Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 × 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma

British Journal of Haematology

Volumn 118, Issue 1, 2002, Pages 90-100

  Jonkhoff, Andries R ^a   De Kreuk, Arne M ^a   Franschman, Gaby ^a   Van Der Lelie, Johannes ^b   Schuurhuis, Gerrit J ^a   Dräger, Angelika M ^a   Zweegman, Sonja ^a   Huijgens, Peter C ^a   Ossenkoppele, Gert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CD34+ thresholds; Haematological recovery; Non frozen haematopoietic stem cells; Stem cell mobilization; Whole blood autologous stem cell transplantation

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BLOOD; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTE;

ADULT; ANTIGENS, CD34; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036069683     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03636.x     Document Type: Article

References (38)

1. Successful cryopreservation of purified autologous CD34+ cells: Influence of freezing parameters on cell recovery and engraftment
2. Granulocyte colony-stimulating factor-mobilized peripheral blood CD34+ cells from children contain the same levels of long-term culture-initiating cells producing the same numbers of colony-forming cells as those from adults, but display greater in vitro monocyte/macrophage potential
3. Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells
4. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy
5. High-dose radioimmunotherapy using rhenium-186-labeled chimeric monoclonal antibody U36 with re-infusion of unprocessed. G-CSF-primed whole blood in head and neck cancer patients
6. Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation
7. Early apoptosis largely accounts for functional impairment of CD34 positive cells in frozen-thawed stem cell grafts
8. Expression of adhesion molecules on CD34+ cells: CD34+ 1-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation
9. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer
10. Blood and marrow transplantation activity in Europe 1997
11. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A groupe d'Etude des lymphomes de l'Adulte study
12. Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: An open study in patients with hematologic malignancies
13. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma
14. Liquid storage of peripheral blood progenitor cells for transplantation
15. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation
16. Storage of unprocessed G-CSF-mobilized whole blood in a modified Leibovitz's L15 medium preserves clonogenic capacity for at least 7 days
17. GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen
18. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma
19. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma
20. G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma
21. Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: Effects of storage media, temperature and time
22. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
23. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma
24. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
25. Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants
26. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
27. The ISHAGE guidelines for CD34+ cell determination by flow cytometry
28. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers
29. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis
30. A predictive model for aggressive non-Hodgkin's lymphoma
31. Mobilization of hematopoietic progenitors in patients with chronic myeloid leukemia
32. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma
33. Effects of the temperature, the duration of frozen storage, and the freezing container on in vitro measurements in human peripheral blood mononuclear cells
34. In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation
35. Cell adhesion molecule expression on CD34+ cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation
36. Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy
37. A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients
38. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized phase II trial in small-cell lung cancer patients